{
    "paper_id": "8c6ecdc297af09289ea5b5761980f71a888d0e21",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Yuheng",
                "middle": [
                    "Xian"
                ],
                "last": "Chen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Shan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "We read with interest the recent paper by Cantini et al., describing the safety and clinical impact of baricitinib therapy in Coronavirus disease 2019 (COVID-19) [1] . COVID-19, caused by 2019 novel coronavirus (2019-nCoV), is increasing rapidly in an epidemic scale and has spread in over 200 countries, causing more than three million confirmed cases and two hundred thousand deaths as of May 5 th , 2020. But currently, there is no vaccine against 2019-nCoV or effective treatment for COVID-19 [2] .",
            "cite_spans": [
                {
                    "start": 162,
                    "end": 165,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 497,
                    "end": 500,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "The typical symptoms of COVID-19 are fever, cough and dyspnea, and the leading cause of mortality is acute respiratory distress syndrome (ARDS). As an immunopathologic event, ARDS is characterized by cytokine storm, which is an excessive systemic inflammatory response triggered by the release of proinflammatory cytokines [3] .",
            "cite_spans": [
                {
                    "start": 323,
                    "end": 326,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "Therefore, diminishing the cytokine storm may be an important part of treatment in patients with severe COVID-19 [4] . Mesenchymal stem cells (MSCs) have been shown to possess powerful immunomodulatory properties and beneficial effects for preventing or reducing the cytokine storm [5] . Hence, MSCs therapy may be a promising option for the treatment of severe COVID-19. On this basis, we conducted a retrospective study to evaluate the treatment efficacy and side effects of MSCs therapy on severe COVID-19.",
            "cite_spans": [
                {
                    "start": 113,
                    "end": 116,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 282,
                    "end": 285,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "All hospitalized patients met the following criteria were consecutively recruited from Clinical grade MSCs were given at a dose of 1\u00d710 6 mononuclear cells per kilogram of weight. Promethazine hydrochloride (intramuscular injection, 25 mg) was used before the injection of MSCs to prevent allergies. For patients received two or three times MSCs therapy, the interval of injection was 5 days. Laboratory tests were conducted 2 to 3 hours before the injection and 48 to 72 hours after the injection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "Data were presented as mean\u00b1SD for continues variables with normal distribution, and median and interquartile range (IQRs) otherwise. Independent continuous variables were compared using the Student t test or the Mann-Whitney test. Paired continuous variables were compared using the paired t test or the Wilcoxon signed-rank test. Categorical variables were compared using the Chi-square test or the Fisher exact test (if any expected value <5). All of the analyses were conducted as 2-sided tests and p<0.05 was considered statistically significant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "Totally, 25 patients were enrolled according to the criteria. Among them, 20 cases (80%) were male and 5 cases (20%) were female. The median age was 70 (IQR: 59,71) years.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "Seven cases received MSCs therapy for one time, 7 cases received for two times and 11 cases received for three times. After MSCs therapy, 16 cases (64%) gained apparently CT scan improvement and all cases gained clinical improvement (Figure 1 ). No fatalities occurred during hospitalization. However, 3 cases experienced treatment related side effects, specifically liver dysfunction, heart failure and allergic rash.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 233,
                    "end": 242,
                    "text": "(Figure 1",
                    "ref_id": null
                }
            ],
            "section": "Dear editor,"
        },
        {
            "text": "The laboratory findings before and after MSCs therapy were shown in Table 1 . There are two main mechanisms of MSCs therapy for COVID-19. Firstly, MSCs could lodge in the pulmonary vascular bed after injection, release anti-inflammatory mediators and reduce the cytokine storm caused by viral infection [7] . Secondly, MSCs could secrete angiopoietin-1 and keratinocyte growth factor, which are pivotal in the restoration of alveolar capillary barriers disrupted by COVID-19 [8] .",
            "cite_spans": [
                {
                    "start": 303,
                    "end": 306,
                    "text": "[7]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 475,
                    "end": 478,
                    "text": "[8]",
                    "ref_id": "BIBREF8"
                }
            ],
            "ref_spans": [
                {
                    "start": 68,
                    "end": 75,
                    "text": "Table 1",
                    "ref_id": null
                }
            ],
            "section": "Dear editor,"
        },
        {
            "text": "In our series, all the patients with severe COVID-19 survived and entered recovery after MSCs therapy, and only 3 patients experienced treatment side effects. This result indicated that MSCs therapy might be an effective therapeutic for severe COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "However, none of the inflammation indexes changed significantly after MSCs therapy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "The reason is unclear, may be related to three factors. Firstly, inflammation indexes, such as WBC counts and CRP were totally normal before MSCs therapy in most cases, which means that cytokine storm was mild to moderate and not serious in these cases. Secondly, relative studies have shown that MSCs will be cleared within 24 to 48 hours after injection [9] . Nevertheless, in our study, laboratory tests were conducted 48 to 72 hours after injection. As a result, we might miss the optimal time to track the changes of inflammation indexes. Thirdly, the inflammation indexes tested and analyzed in this study were limited, and whether other cytokines like IL-2 and IL-7 would decrease after MSCs therapy is unknown.",
            "cite_spans": [
                {
                    "start": 356,
                    "end": 359,
                    "text": "[9]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "Additionally, we found that the serum levels of LAC, cTnT and CK-MB were elevated significantly after MSCs therapy. The reason is unclear, but remind us that the use of MSCs therapy should be extremely cautious in patients with metabolic acidosis or coronary heart disease. Moreover, the infusion speed of MSCs must be slow enough. In this study, we injected MSCs saline solution at a speed of ~20 drops per minute, but there was still a patient experiencing heart failure while on treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "The major limitations of this study were small series, retrospective and no placebo.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "Therefore, additional prospective studies involving large cohort of patients are needed in order to confirm and supplement the present findings.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        },
        {
            "text": "In conclusion, we suggested that MSCs therapy might be a promising option for the treatment of severe COVID-19, but should be used cautiously, especially in patients with metabolic acidosis or coronary heart disease. Values are presented as mean \u00b1 SD or median (P25, P75). WBC, White blood cells; CRP, C-reaction protein; PCT, procalcitonin; IL-6, interleukin-6; LAC, lactate; ALT, alanine aminotransferase; Cr, creatinine; cTnT, cardiac troponin T; CK-MB, creatine kinase-MB.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear editor,"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Cantini",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Niccoli",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Matarrese",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Nicastri",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Stobbione",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Goletti",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "The Journal of infection",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jinf.2020.04.017"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "The epidemiology, diagnosis and treatment of COVID-19",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhai",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ding",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Long",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105955"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Channappanavar",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Seminars in immunopathology",
            "volume": "39",
            "issn": "5",
            "pages": "529--539",
            "other_ids": {
                "DOI": [
                    "10.1007/s00281-017-0629-x"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "The pathogenesis and treatment of the `Cytokine Storm' in COVID-19",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "The Journal of infection",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jinf.2020.03.037"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Cytokine storm intervention in the early stages of COVID-19 pneumonia",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Liao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhi",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cytokine & growth factor reviews",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.cytogfr.2020.04.002"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19. The European respiratory journal",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Khoury",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cuenca",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "F"
                    ],
                    "last": "Cruz",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "E"
                    ],
                    "last": "Figueroa",
                    "suffix": ""
                },
                {
                    "first": "Prm",
                    "middle": [],
                    "last": "Rocco",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Weiss",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1183/13993003.00858-2020"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Atluri",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Manchikanti",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Hirsch",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Pain physician",
            "volume": "23",
            "issn": "2",
            "pages": "71--83",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "February 20 th , 2020 to March 30 th , 2020: (1) definite diagnosis of severe COVID-19; (2) age\u226518 years; (3) receiving MSCs therapy. All patients have signed written informed consent in line with the Declaration of Helsinki. The diagnosis of severe COVID-19 was made according to the Guideline for Diagnosis and Treatment for COVID-19 of National Health Commission of China (real-time RT-PCR assay; (2) respiratory distress, RR\u226530 beats/min; (3) oxygen saturation level\u226493% in resting state; (4) arterial partial pressure of oxygen (PaO2)/fraction of inspiration O2 (FiO2) \u2264300 mmHg (1 mmHg=0.133 kPa).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Inflammation indexes, including white blood cells (WBC) counts, C-reaction protein (CRP), procalcitonin (PCT) and interleukin-6 (IL-6) did not change significantly after MSCs therapy. Similarly, significant changes of IgG and IgM were not found either. However, the serum levels of lactate (LAC), cardiac troponin T (cTnT) and creatine kinase-MB (CK-MB) elevated significantly after MSCs therapy (p<0.05).",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Moodley YP (2018) Mesenchymal stromal cell infusion modulates systemic immunologicalresponses in stable COPD patients: a phase I pilot study. The European respiratory journal 51",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "The authors wish to thank all the clinicians for their hard work and sacrifices.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Acknowledgements"
        },
        {
            "text": "As a retrospective study and data analysis was conducted anonymously, written informed consent was not required in this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethical standards"
        },
        {
            "text": "The authors declare that there are no conflicts of interest. Fig.1 Chest CT scans of severe COVID-19 cases before and after MSCs therapy. A, cases with apparently CT scan improvement; B, cases without apparently CT scan improvement",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 61,
                    "end": 66,
                    "text": "Fig.1",
                    "ref_id": null
                }
            ],
            "section": "Conflicts of interest"
        }
    ]
}